Sarepta Therapeutics (SRPT) Aandelenoverzicht
Sarepta Therapeutics, Inc. is een biofarmaceutisch bedrijf dat zich richt op het ontdekken en ontwikkelen van RNA-gerichte therapeutica, het siRNA-platform, gentherapie en andere genetische therapeutische modaliteiten voor de behandeling van zeldzame ziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
SRPT Community Fair Values
Create NarrativeSee what 80 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sarepta Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$16.96 |
| 52 Week Hoogtepunt | US$43.92 |
| 52 Week Laag | US$10.42 |
| Bèta | 0.25 |
| 1 maand verandering | -17.99% |
| 3 maanden verandering | -10.17% |
| 1 Jaar Verandering | -56.28% |
| 3 jaar verandering | -86.84% |
| 5 jaar verandering | -77.93% |
| Verandering sinds IPO | -56.51% |
Recent nieuws en updates
Analyseartikel • May 14
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News
Investors appear disappointed with Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) recent earnings, despite the decent...
Narratiefupdate • May 07
SRPT: 2026 Reset Year Guidance Will Pressure Overvalued Shares
Analysts have lowered their average price target on Sarepta Therapeutics by about $64. The change is tied to updated 2026 guidance, reduced revenue expectations for Elevidys and PMO products, and a lower future P/E assumption, despite generally mixed views on the siRNA and DM1 programs.Recent updates
Analyseartikel • May 14
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Solid Earnings, But It Is Not All Good News
Investors appear disappointed with Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) recent earnings, despite the decent...Narratiefupdate • May 07
SRPT: 2026 Reset Year Guidance Will Pressure Overvalued Shares
Analysts have lowered their average price target on Sarepta Therapeutics by about $64. The change is tied to updated 2026 guidance, reduced revenue expectations for Elevidys and PMO products, and a lower future P/E assumption, despite generally mixed views on the siRNA and DM1 programs.
Narratiefupdate • Apr 22
SRPT: 2026 Guidance And siRNA Pipeline Readouts Will Shape Upside Potential
Sarepta Therapeutics' updated analyst price target has shifted modestly, reflecting a lower fair value estimate of $37.42 and a reduced future P/E assumption as analysts weigh mixed siRNA data, updated 2026 revenue guidance, and varying views on Elevidys and the PMO franchise. Analyst Commentary Recent Street research on Sarepta shows a wide range of views, but several bullish analysts are leaning into updated company guidance and new clinical datapoints when revisiting their models.
Narratiefupdate • Apr 07
SRPT: Future Returns Will Depend On 2026 Reset And Mixed Pipeline Signals
Analysts have lifted the blended price target for Sarepta Therapeutics by about $1 to $2, reflecting recent target revisions that balance cautious views on Elevidys revenue guidance and siRNA data quality with more constructive perspectives on early DM1 results and updated 2026 sales and expense models. Analyst Commentary Recent research paints a mixed picture for Sarepta, with analysts updating models around Elevidys, siRNA programs, and early DM1 data.Seeking Alpha • Mar 24
Sarepta Therapeutics: A $2B Business Priced Like It's Broken
Summary Sarepta Therapeutics is navigating a transition from a profitable rare-disease company to a capital-intensive, multi-platform biotech, with Elevidys as one of the key value drivers. FY25 revenue grew 16% to $2.2 billion, but profitability deteriorated sharply due to surging R&D, inventory write-downs, and manufacturing issues, resulting in a $713 million GAAP net loss. Regulatory setbacks for Elevidys, including a restricted label and safety concerns, have compressed SRPT’s valuation and introduced significant execution risk and revenue unpredictability. I maintain a Hold rating, citing limited near-term visibility, but see long-term optionality in gene therapy and the expanding siRNA pipeline, with 2026 as a pivotal year for key data readouts. Read the full article on Seeking AlphaNarratiefupdate • Mar 23
SRPT: Future Upside Will Hinge On 2026 Gene Therapy Launch Reset
Analysts made a modest upward adjustment to Sarepta Therapeutics' fair value estimate, reflecting updated models around Elevidys launch pacing, 2026 revenue guidance, and revised expectations for profitability and future P/E multiples following recent Q4 results and regulatory commentary. Analyst Commentary Street research on Sarepta around the Q4 update and 2026 guidance reflects a wide range of views on execution risk, Elevidys launch pacing, and the durability of the exon-skipping and gene therapy portfolio.Narratiefupdate • Mar 09
SRPT: Future Upside Will Depend On 2026 Gene Therapy Execution
The analyst price target for Sarepta Therapeutics has moved slightly lower to align with revised 2026 revenue expectations and product launch assumptions, with recent Street targets stepping down in a range from about $45 to $8 as analysts recalibrate Elevidys and other franchise contributions. Analyst Commentary Street views on Sarepta are split, with several firms cutting price targets after management issued 2026 revenue guidance that appears lower than earlier assumptions, while others still see room for execution on the Elevidys and exon-skipping franchises to support value over time.Narratiefupdate • Feb 22
SRPT: Future Risk Reward Will Hinge On Elevidys Execution And Patent Overhang
The analyst price target for Sarepta Therapeutics has been raised by about $0.80. Analysts point to slightly higher fair value estimates, a modestly firmer long term profit margin outlook and updated P/E assumptions, even as they factor in a slightly higher discount rate and restrained revenue expectations.Narratiefupdate • Feb 08
SRPT: Upcoming 2026 Clinical And Regulatory Milestones Will Drive Future Upside
Analysts have edged their price targets on Sarepta Therapeutics higher, with a modest fair value increase of about $0.20 per share. Slightly stronger long run profit expectations more than offset softer modeled revenue growth and a small trim to the assumed future P/E multiple.Narratiefupdate • Jan 25
SRPT: Gene Therapy Catalysts And Access Updates Will Drive Future Upside
Analysts nudged their price target on Sarepta Therapeutics slightly higher, lifting fair value by about US$0.33 to US$39.90 as they factor in updated expectations for Elevidys sales, profitability, and a modestly higher discount rate. Analyst Commentary Recent research on Sarepta highlights a split view on Elevidys, with some pointing to softer near term sales and others focusing on what they see as growing adoption and a broader pipeline story.Narratiefupdate • Jan 10
SRPT: Elevidys Adoption And Pipeline Progress Will Drive Future Upside
Analysts have reset their fair value estimate for Sarepta Therapeutics from US$55.90 to US$39.56. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple following recent research that highlights both improved confidence in Elevidys adoption and ongoing caution from some covering firms.Narratiefupdate • Dec 25
SRPT: Future Risk Reward Will Hinge On Evolving Safety And Coverage Decisions
The analyst price target for Sarepta Therapeutics has been raised slightly, by about $0.20 per share. Analysts attribute this to stronger than expected Elevidys adoption, supportive payer coverage, and a more favorable risk and reward profile, despite unchanged long-term growth and margin assumptions.Narratiefupdate • Dec 11
SRPT: Safety Reviews And Payer Decisions Will Shape Future Risk Reward Balance
Sarepta Therapeutics' fair value estimate has been raised modestly to approximately $20.43 from $19.91, as analysts factor in stronger than expected Elevidys adoption and a more favorable risk or reward profile, despite only incremental improvements in revenue growth and discount rate assumptions. Analyst Commentary Street research on Sarepta has turned more constructive at the margin, with multiple models recalibrated around stronger Elevidys uptake and a clearer path to reimbursement.Analyseartikel • Dec 04
There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders would be excited to see that the share price has had a great...Narratiefupdate • Nov 27
SRPT: Ongoing Regulatory Reviews And Safety Updates Will Shape Near-Term Prospects
The analyst price target for Sarepta Therapeutics has been modestly reduced from approximately $21.55 to $19.91. Analysts express mixed expectations based on recent shifts in profit margin projections and ongoing evaluations of Elevidys adoption and safety dynamics.Narratiefupdate • Nov 05
SRPT: Upcoming Clinical Data Will Drive Renewed Momentum In Gene Therapy Efforts
Sarepta Therapeutics' analyst price target has been revised downward from approximately $22.88 to $21.55 per share. Analysts cite ongoing concerns over Elevidys uptake, modest improvements to revenue outlook, and persistent profit margin pressures.Analyseartikel • Oct 18
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Despite an already strong run, Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares have been powering on, with a gain of...Narratiefupdate • Sep 26
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ consensus price target has been lowered from $23.96 to $22.88, primarily due to ongoing Elevidys safety concerns, regulatory uncertainty, and negative sentiment over recent management decisions, outweighing the short-term relief from improved liquidity and regulatory clarity. Analyst Commentary Elevidys safety concerns, including recent patient deaths and new serious adverse event reports, have sustained regulatory uncertainty and contributed to ongoing negative sentiment and price target reductions by Bearish analysts.Narratiefupdate • Sep 04
Upcoming ELEVIDYS And Gene Therapy Updates Will Restore Patient Trust
Sarepta Therapeutics’ price target remains under pressure due to persistent safety concerns and regulatory uncertainty surrounding Elevidys, limited market scope after clinical setbacks and halted non-ambulatory development, and skepticism about long-term cash generation, resulting in a maintained consensus analyst price target of $23.84. Analyst Commentary Continued safety concerns surrounding Elevidys, particularly following patient deaths and serious adverse events (notably acute liver failure in non-ambulatory patients and new adverse event reports), have caused repeated reductions in revenue forecasts and increased uncertainty about regulatory approval and commercial uptake.Analyseartikel • May 29
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
Key Insights Sarepta Therapeutics to hold its Annual General Meeting on 5th of June CEO Doug Ingram's total...Analyseartikel • May 08
The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
Today is shaping up negative for Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shareholders, with the analysts delivering...Analyseartikel • Apr 20
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%
To the annoyance of some shareholders, Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) shares are down a considerable 27% in...Seeking Alpha • Mar 18
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Summary Sarepta Therapeutics stock dropped over 20% after a patient treated with Elevidys for DMD died from acute liver failure, raising safety concerns. Despite the incident, Sarepta maintains that the benefit-risk profile of Elevidys remains positive, and over 800 patients have been treated without such severe adverse events. Sarepta's strong financial performance and growth prospects for Elevidys and other therapies may be clouded somewhat by potential regulatory and market reactions to the safety event. Given the uncertainty and need for further data, I am revising my rating on SRPT stock from "Buy" to "Hold" to exercise caution. Read the full article on Seeking AlphaAnalyseartikel • Mar 05
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement
Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a buy...Seeking Alpha • Mar 04
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Summary Sarepta Therapeutics' stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD, and DM1, with significant market potential, though not as large as DMD. Despite leadership in the DMD market, Sarepta faces risks from clinical trial outcomes, revenue concentration on Elevidys, and potential competition. Read the full article on Seeking AlphaAnalyseartikel • Jan 22
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jan 16
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Summary Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals. Sarepta's positive net income and ongoing clinical programs, including a promising partnership with Arrowhead Pharmaceuticals, support a valuation upgrade, with potential for market cap to exceed $15bn. Read the full article on Seeking AlphaRendement voor aandeelhouders
| SRPT | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -9.2% | -1.6% | -0.8% |
| 1Y | -56.3% | 34.4% | 27.1% |
Rendement versus industrie: SRPT presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 32.9 % opleverde.
Rendement versus markt: SRPT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 26.7 % opleverde.
Prijsvolatiliteit
| SRPT volatility | |
|---|---|
| SRPT Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van SRPT is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van SRPT is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1980 | 835 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., een biofarmaceutisch bedrijf in commerciële fase, richt zich op het ontdekken en ontwikkelen van RNA-gerichte therapeutica, siRNA-platform, gentherapie en andere genetische therapeutische modaliteiten voor de behandeling van zeldzame ziekten. Het biedt EXONDYS 51 voor de behandeling van Duchenne bij patiënten met een bevestigde mutatie van het dystrofine gen dat geschikt is voor exon 51 skipping; VYONDYS 53 voor de behandeling van Duchenne bij patiënten met een bevestigde mutatie van het dystrofine gen dat geschikt is voor exon 53 skipping; AMONDYS 45 voor de behandeling van Duchenne bij patiënten met een bevestigde mutatie van het dystrofine gen dat geschikt is voor het overslaan van exon 45; en ELEVIDYS, een AAV-gebaseerde gentherapie, die gecontra-indiceerd is bij patiënten met een deletie in exon 8 en/of exon 9 in het Duchenne gen. Het bedrijf ontwikkelt ook SRP-9003, een gentherapieprogramma voor de behandeling van LGMD2E; SRP-1001 voor het selectief richten op en uitschakelen van DUX4 met behulp van RNAi in Fase 1/2a klinische studies; en SRP-1003 voor het verminderen van de expressie van het DMPK-gen in Fase 1/2a klinische studies.
Sarepta Therapeutics, Inc. Samenvatting
| SRPT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.81b |
| Inkomsten(TTM) | US$65.06m |
| Inkomsten(TTM) | US$2.18b |
27.5x
Koers/Winstverhouding0.8x
P/S-verhoudingIs SRPT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SRPT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.18b |
| Kosten van inkomsten | US$2.33b |
| Brutowinst | -US$141.65m |
| Overige uitgaven | -US$206.71m |
| Inkomsten | US$65.06m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.62 |
| Brutomarge | -6.49% |
| Nettowinstmarge | 2.98% |
| Schuld/Eigen Vermogen Verhouding | 55.7% |
Hoe presteerde SRPT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 02:09 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sarepta Therapeutics, Inc. wordt gevolgd door 50 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |